S&P 500
(0.80%) 5 277.51 points

Dow Jones
(1.51%) 38 686 points

Nasdaq
(-0.01%) 16 735 points

Oil
(-0.94%) $77.18

Gas
(0.35%) $2.58

Gold
(-0.79%) $2 347.70

Silver
(-3.10%) $30.56

Platinum
(0.63%) $1 044.50

USD/EUR
(-0.17%) $0.921

USD/NOK
(-0.49%) $10.49

USD/GBP
(-0.05%) $0.785

USD/RUB
(0.15%) $90.40

Realtime updates for Syndax Pharmaceuticals [SNDX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

BUY

80.00%
return 4.54%

SELL

40.00%
return 0.25%

Last Updated31 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

-0.10% $ 19.27

BUY 154393 min ago

@ $22.05

Issued: 14 Feb 2024 @ 15:38

Return: -12.61%

Previous signal: Feb 13 - 15:50

Previous signal: Sell

Return: 4.26 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD)...

Stats
Today's Volume	794 228
Average Volume	1.06M
Market Cap	1.64B
EPS	$0 ( 2024-05-13 )
Next earnings date	( $-0.920 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.95
ATR14	$0.0120 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Rizo Aleksandra	Buy	35 000	Stock Options (Right to buy)
2024-05-15	Rizo Aleksandra	Buy	0
2024-02-07	Metzger Michael A	Buy	214 500	Stock Options (Right to buy)
2024-02-07	Metzger Michael A	Buy	39 000	Common Stock
2024-02-07	Metzger Michael A	Buy	107 250	Common Stock

INSIDER POWER
47.29
Last 96 transactions
Buy: 2 745 313 \| Sell: 1 084 384

Volume Correlation

Long: 0.38 (neutral)

Short: -0.38 (neutral)

Signal:(51.363) Neutral

Syndax Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Syndax Pharmaceuticals Correlation - Currency/Commodity

-0.61
( weak negative )

-0.67
( moderate negative )

0.00
( neutral )

0.34
( neutral )

0.16
( neutral )

0.73
( moderate )

Syndax Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-2.98

FY	2023
Revenue:	$0
Gross Profit:	$-12 000.00 (0.00 %)
EPS:	$-2.98

FY	2022
Revenue:	$0
Gross Profit:	$-454 000 (0.00 %)
EPS:	$-2.37

FY	2021
Revenue:	$139.71M
Gross Profit:	$0.00 (0.00 %)
EPS:	$0.480

Financial Reports:

No articles found.

Syndax Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.

Total Execution Time: 1.7621250152588 seconds
Number of API calls: 2
Number of DB calls: 8